TruGraf Long-term Clinical Outcomes Study

  • End date
    Nov 5, 2023
  • participants needed
  • sponsor
    Transplant Genomics, Inc.
Updated on 5 May 2021


This is a prospective, multi-center, observational study. Subjects will have TruGraf and TRAC testing at study enrollment and thereafter every 3 months. In addition subjects will have TRAC testing at any time there is a clinical suspicion of acute rejection. Data collection for the primary objective extends over a 2-year period.


Several studies have validated TruGraf in stable renal transplant patients to rule out subclinical acute rejection. These studies generally evaluated the diagnostic value of TruGraf at single timepoints. Thus the value of serial monitoring and changes over time has not been previously investigated. In addition, no study has assessed TruGraf and TRACin a serial and longitudinal fashion.

Therefore the aim of this study is to evaluate the impact of serial monitoring renal transplant patients with both TruGraf and TRAC on long term outcomes.

Condition Renal Transplant Rejection, Kidney Transplant Rejection
Treatment Patients monitored with TruGraf and TRAC testing
Clinical Study IdentifierNCT04491552
SponsorTransplant Genomics, Inc.
Last Modified on5 May 2021


Yes No Not Sure

Inclusion Criteria

Written informed consent and HIPAA authorization
At least 18 years of age
Recipient of a primary or subsequent deceased-donor or living-donor kidney transplant
At least 1-year post-transplant (+/- 2 months)
Stable serum creatinine (current serum creatinine < 2.3 mg/dl, < 20% increase compared to the average of the previous 3 serum creatinine levels)
Treated with any immunosuppressive regimen, and
Selected by provider to undergo TruGraf and TRAC testing as part of post-transplant care; and
Has Medicare Part B coverage

Exclusion Criteria

Recipient of a combined organ transplant with an extra-renal organ and/or islet cell transplant
Recipient of a previous non-renal solid organ and/or islet cell transplant
Known to be pregnant
Known to be infected with HIV
Known to have BK nephropathy
Known to have nephrotic proteinuria (urine protein > 3 gm/day)
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact


Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note